Frequency Therapeutics, Inc. - FREQ STOCK NEWS

Frequency Therapeutics, Inc. (Nasdaq: FREQ) announced that CEO David L. Lucchino will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on April 14 at 8:00 a.m. EDT. Investors can access a live webcast of the presentation on Frequency's website, with a replay available after the event. The company focuses on developing medicines that activate progenitor cells to repair damage from degenerative diseases. Its lead product, FX-322, aims to regenerate auditory hair cells for hearing restoration and is under evaluation in ongoing clinical studies.

Frequency Therapeutics, Inc. (Nasdaq: FREQ) reported business updates and financial results for Q4 and the year ending December 31, 2020. The firm highlighted important data from two clinical studies involving FX-322 for sensorineural hearing loss, indicating statistically significant improvements in speech intelligibility. Despite this, interim Phase 2a study results showed no clear benefits of FX-322 over placebo. Financially, the company generated $10 million in Q4 revenue, with R&D expenses increasing to $11.8 million. The net loss for 2020 was $26.5 million, reflecting rising operational costs.

Frequency Therapeutics (Nasdaq: FREQ) announced topline day-90 data from its FX-322 Phase 2a study, indicating no hearing improvements in subjects with sensorineural hearing loss compared to placebo after four weekly injections. No serious adverse events were reported. However, a parallel single-dose study revealed 34% of subjects saw a significant improvement in Word Recognition scores. The company plans to focus on further development of FX-322 as a single-dose regimen, having learned from the Phase 2a results, which suggested a need to advance its development strategy.

Frequency Therapeutics, Inc. (Nasdaq: FREQ) announced positive results from its FX-322 Phase 1/2 study published in Otology & Neurotology. The study showcased statistically significant improvements in word recognition and words-in-noise scores for adults with acquired sensorineural hearing loss (SNHL) following a single dose of FX-322, with p-values of 0.029 and 0.012 respectively. Notably, the treatment was well tolerated, and no significant changes were observed in the placebo group. FX-322 aims to regenerate auditory hair cells and is currently undergoing a larger Phase 2a study with results expected soon.

Frequency Therapeutics, Inc. (Nasdaq: FREQ) has appointed Quentin McCubbin, Ph.D., as its new chief manufacturing officer. Dr. McCubbin will lead technical operations, including drug product formulation and supply chain management, to bolster the development of the company's product pipeline. He previously held a senior position at Cerevel Therapeutics and has extensive experience at Takeda/Millennium Pharmaceuticals. This strategic hire is aimed at advancing Frequency’s FX-322 program, which seeks to treat sensorineural hearing loss, and expanding its clinical pipeline.

Frequency Therapeutics, Inc. (Nasdaq: FREQ) has announced that CEO David L. Lucchino will present a company overview at the 39th annual J.P. Morgan Healthcare conference on January 13th at 7:30 a.m. ET, followed by a Q&A session at 8:00 a.m. ET. The presentation will be available via live webcast on the company’s investor website. Frequency is focused on developing medicines that activate progenitor cells to treat degenerative diseases, with its lead candidate FX-322 showing promising results in regenerating auditory hair cells and improving hearing function in patients with sensorineural hearing loss.

Frequency Therapeutics (Nasdaq: FREQ) is hosting a virtual event on January 19, 2021, to discuss interventions for acquired sensorineural hearing loss (SNHL) and the transformative potential of FX-322. Leading experts in the field will present findings from ongoing clinical studies, including a Phase 2a study in patients with mild to moderately severe SNHL. Results are expected in Q1 and Q2 2021. FX-322 aims to regenerate auditory hair cells, addressing a condition affecting over 40 million people in the U.S.

Frequency Therapeutics (Nasdaq: FREQ) has appointed Peter P. Pfreundschuh as the new chief financial officer. Pfreundschuh brings over 20 years of experience in finance and business development, having previously served in high-ranking positions at UroGen, Sucampo Pharmaceuticals, Immunomedics, and CircuLite. His role will focus on financial strategy and overseeing business operations. The company aims to advance its lead product FX-322 for hearing loss and expand its pipeline, with significant clinical milestones anticipated in 2021, including key study readouts for FX-322.

Frequency Therapeutics, Inc. (Nasdaq: FREQ) provided updates for Q3 2020, focusing on its lead product candidate FX-322 for acquired sensorineural hearing loss (SNHL). The company plans to analyze day-90 data from its Phase 2a study in late Q1 2021 and expects to report end of Phase 2a results in late Q2 2021. Financially, revenue decreased to $11.2 million in Q3 2020, compared to $24.2 million in Q3 2019. Research and development expenses rose significantly, contributing to a net loss of $5.3 million, up from $0.6 million year-over-year. The cash position remains strong at $224.2 million.